Health Care & Life Sciences » Pharmaceuticals | Collegium Pharmaceutical Inc.

Collegium Pharmaceutical Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
7,551.00
1,634.00
95,697.00
153,225.00
118,697.00
146,633
Total Accounts Receivable
-
-
-
2,129.00
9,969.00
77,946
Inventories
-
-
-
1,316.00
1,813.00
7,817
Other Current Assets
710.00
527.00
833.00
1,905.00
3,005.00
5,116
Total Current Assets
8,261.00
2,161.00
96,530.00
158,575.00
133,484.00
237,512
Net Property, Plant & Equipment
693.00
514.00
738.00
1,038.00
1,826.00
9,274
Total Investments and Advances
80.00
80.00
97.00
97.00
97.00
-
Intangible Assets
-
-
-
2,103.00
-
44,255
Other Assets
-
2,335.00
353.00
204.00
161.00
204
Total Assets
9,034.00
5,090.00
97,718.00
162,017.00
135,568.00
291,245
ST Debt & Current Portion LT Debt
333.00
6,194.00
2,667.00
2,667.00
1,479.00
Accounts Payable
-
-
-
9,106.00
5,684.00
Other Current Liabilities
2,285.00
4,223.00
5,765.00
13,823.00
24,325.00
Total Current Liabilities
2,618.00
10,417.00
8,432.00
25,596.00
31,488.00
Long-Term Debt
640.00
6,813.00
4,146.00
1,479.00
-
Other Liabilities
194.00
101.00
68.00
34.00
-
Total Liabilities
3,452.00
17,331.00
12,646.00
27,109.00
31,488.00
Common Equity (Total)
68,225.00
89,348.00
85,072.00
134,908.00
104,080.00
Total Shareholders' Equity
68,225.00
89,348.00
85,072.00
134,908.00
104,080.00
Total Equity
68,225.00
89,348.00
85,072.00
134,908.00
104,080.00
Liabilities & Shareholders' Equity
9,034.00
5,090.00
97,718.00
162,017.00
135,568.00
Non-Equity Reserves
73,807.00
77,107.00
-
-
-

About Collegium Pharmaceutical

View Profile
Address
100 Technology Center Drive
Stoughton Massachusetts 02072
United States
Employees -
Website http://www.collegiumpharma.com
Updated 07/08/2019
Collegium Pharmaceutical, Inc. engages in the development and commercialization of next-generation, abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER, and ONSOLIS. Xtampza ER provides pain control while maintaining its extended-release drug release profile after being subjected to common methods of abuse and accidental misuse.